SG11202002105WA - Methods for making and using endoxifen - Google Patents
Methods for making and using endoxifenInfo
- Publication number
- SG11202002105WA SG11202002105WA SG11202002105WA SG11202002105WA SG11202002105WA SG 11202002105W A SG11202002105W A SG 11202002105WA SG 11202002105W A SG11202002105W A SG 11202002105WA SG 11202002105W A SG11202002105W A SG 11202002105WA SG 11202002105W A SG11202002105W A SG 11202002105WA
- Authority
- SG
- Singapore
- Prior art keywords
- endoxifen
- making
- methods
- Prior art date
Links
- MHJBZVSGOZTKRH-IZHYLOQSSA-N 4-Hydroxy-N-desmethyltamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCNC)=CC=1)/C1=CC=C(O)C=C1 MHJBZVSGOZTKRH-IZHYLOQSSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/02—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions involving the formation of amino groups from compounds containing hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C213/10—Separation; Purification; Stabilisation; Use of additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762556799P | 2017-09-11 | 2017-09-11 | |
US201762556884P | 2017-09-11 | 2017-09-11 | |
US201862624787P | 2018-01-31 | 2018-01-31 | |
US201862693885P | 2018-07-03 | 2018-07-03 | |
PCT/US2018/050272 WO2019051416A1 (en) | 2017-09-11 | 2018-09-10 | METHODS FOR THE MANUFACTURE AND USE OF ENDOXIFEN |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002105WA true SG11202002105WA (en) | 2020-04-29 |
Family
ID=65635248
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002105WA SG11202002105WA (en) | 2017-09-11 | 2018-09-10 | Methods for making and using endoxifen |
Country Status (12)
Country | Link |
---|---|
US (4) | US11261151B2 (ko) |
EP (1) | EP3681491A4 (ko) |
JP (2) | JP2020533283A (ko) |
KR (1) | KR20200052349A (ko) |
CN (2) | CN111328280A (ko) |
AU (2) | AU2018329202B2 (ko) |
CA (1) | CA3073836A1 (ko) |
IL (2) | IL272924B2 (ko) |
MX (1) | MX2020002649A (ko) |
SG (1) | SG11202002105WA (ko) |
TW (1) | TWI793165B (ko) |
WO (1) | WO2019051416A1 (ko) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2018329202B2 (en) | 2017-09-11 | 2022-10-27 | Atossa Therapeutics, Inc. | Methods for making and using endoxifen |
CN114302717A (zh) * | 2019-07-03 | 2022-04-08 | 阿托萨治疗学公司 | 内昔芬的持续释放组合物 |
CN110564962B (zh) * | 2019-10-14 | 2020-12-22 | 中南大学 | 一种黑白钨混合矿的冶炼方法 |
CN113975279A (zh) * | 2021-10-13 | 2022-01-28 | 复旦大学附属肿瘤医院 | 维拉佐酮及其衍生物在制备抗肿瘤药物中的应用 |
TW202340135A (zh) * | 2022-01-12 | 2023-10-16 | 美商阿托薩醫療公司 | (z)—因多昔芬之組合物及其富集方法 |
WO2023211939A1 (en) * | 2022-04-26 | 2023-11-02 | Atossa Therapeutics, Inc. | High dose endoxifen formulations and methods of use |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT951631B (it) | 1971-03-18 | 1973-07-10 | Richardson Merrell Spa | Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi |
GB8604528D0 (en) | 1986-02-24 | 1986-04-03 | Ici Plc | Therapeutic agents |
US6881548B2 (en) | 1997-05-23 | 2005-04-19 | A&G Pharmaceutical, Inc. | Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
US6638727B1 (en) | 1999-01-26 | 2003-10-28 | Cytyc Health Corporation | Methods for identifying treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer |
US6398765B1 (en) | 1999-03-01 | 2002-06-04 | Pro Duct Health, Inc. | Apparatus, methods and kits for simultaneous delivery of a substance to multiple breast milk ducts |
US6245352B1 (en) | 1999-04-27 | 2001-06-12 | Eli Lilly And Company | Pharmaceutical formulation |
WO2001001962A1 (en) | 1999-07-05 | 2001-01-11 | Idea Ag. | A method for the improvement of transport across adaptable semi-permeable barriers |
GB0000313D0 (en) | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
GB0008172D0 (en) | 2000-04-05 | 2000-05-24 | Astrazeneca Ab | Therapy |
EP1572171B1 (en) | 2002-12-18 | 2009-04-22 | Laboratoires Besins International | Reduction of breast density with 4-hydroxy tamoxifen |
JP4938237B2 (ja) | 2002-12-18 | 2012-05-23 | ラボラトワール ブザン アンテルナスィヨナル | 4−ヒドロキシタモキシフェンによる乳房痛の治療 |
EP1952810B1 (en) | 2003-04-01 | 2014-01-08 | Besins Healthcare Luxembourg SARL | Treatment of breast cancer with 4-hydroxytamoxifen |
WO2005000241A2 (en) | 2003-06-23 | 2005-01-06 | Macrochem Corporation | Compositons and methods for topical administration |
US7531578B2 (en) | 2003-09-18 | 2009-05-12 | City Of Hope | Compounds and methods for treating breast cancer and other diseases |
US7968532B2 (en) | 2003-12-15 | 2011-06-28 | Besins Healthcare Luxembourg | Treatment of gynecomastia with 4-hydroxy tamoxifen |
WO2005070951A1 (en) | 2004-01-16 | 2005-08-04 | Cedarburg Pharmaceuticals, Inc. | Exemestane and its intermediates and methods of making the same |
WO2005089511A2 (en) | 2004-03-19 | 2005-09-29 | Transform Pharmaceuticals, Inc. | Novel pharmaceutical forms, and methods of making and using the same |
US7507769B2 (en) | 2004-03-22 | 2009-03-24 | Laboratoires Besins International | Treatment and prevention of benign breast disease with 4-hydroxy tamoxifen |
WO2006121532A2 (en) | 2005-03-31 | 2006-11-16 | Mytogen, Inc. | Treatment for heart disease |
US7705159B2 (en) | 2005-07-06 | 2010-04-27 | Sicor, Inc. | Process for the preparation of letrozole |
US20080319092A1 (en) | 2005-08-05 | 2008-12-25 | Nuvo Research Inc. | Transdermal Drug Delivery Formulation |
JP4000185B2 (ja) | 2005-10-12 | 2007-10-31 | 興和株式会社 | 乳癌及び/又は乳腺炎治療用イオントフォレシス製剤 |
WO2007067773A2 (en) | 2005-12-09 | 2007-06-14 | Mayo Foundation For Medical Education And Research | Assessing outcomes for breast cancer patients by determining cyp2d6 genotype |
JP5294874B2 (ja) | 2005-12-20 | 2013-09-18 | インサイト・コーポレイション | インドールアミン2,3−ジオキシゲナーゼのモジュレーターとしてのn−ヒドロキシアミジノヘテロ環 |
US9308181B2 (en) | 2006-03-06 | 2016-04-12 | Nuvo Research Inc. | Topical formulations, systems and methods |
EP2029557A1 (en) | 2006-06-05 | 2009-03-04 | Cadila Healthcare Ltd. | A process for preparing pure anastrozole |
KR20090094811A (ko) | 2006-10-05 | 2009-09-08 | 파나세아 바이오테크 리미티드 | 새로운 형태의 주입형 데포조성물 및 이를 조제하기 위한 방법 |
JP2010510327A (ja) | 2006-11-21 | 2010-04-02 | ジャイナ ファーマシューティカルズ,インコーポレーテッド | エンドキシフェンの方法および組成物 |
US20120164075A1 (en) * | 2006-11-21 | 2012-06-28 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of mammalian diseases |
US20090291134A1 (en) | 2006-11-21 | 2009-11-26 | Jina Pharmaceuticals, Inc. | Endoxifen methods and compositions in the treatment of psychiatric and neurodegenerative diseases |
US20080207644A1 (en) | 2006-11-27 | 2008-08-28 | Sonis Stephen T | Therapeutic materials and methods |
WO2008067991A2 (en) | 2006-12-08 | 2008-06-12 | Antares Pharma Ipl Ag | Skin-friendly drug complexes for transdermal administration |
WO2008113177A1 (en) | 2007-03-20 | 2008-09-25 | Centre De Recherche Sur Les Biotechnologies Marines | Compositions comprising polyunsaturated fatty acid monoglycerides or derivatives thereof and uses thereof |
MX337408B (es) | 2007-03-22 | 2016-03-03 | Berg Llc | Formulaciones topicas que tienen biodisponibilidad aumentada. |
US20090068190A1 (en) | 2007-08-29 | 2009-03-12 | Drugtech Corporation | Anti-proliferative combinations |
AR068409A1 (es) | 2007-09-14 | 2009-11-18 | Drugtech Corp | Composiciones farmaceuticas, transdermicas sin alcohol |
EP2212301B1 (en) | 2007-11-28 | 2012-02-29 | Fresenius Kabi Oncology Limited | An improved process for preparation of letrozole and its intermediates |
WO2009120999A2 (en) | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Use of an endoxifen prodrug for treatment of breast cancer |
US20100069781A1 (en) | 2008-04-15 | 2010-03-18 | Johansen Jerald A | Device and method for accessing and treating ducts of mammary glands |
US8063249B1 (en) | 2008-04-25 | 2011-11-22 | Olema Pharmaceuticals, Inc. | Substituted triphenyl butenes |
KR101649548B1 (ko) | 2008-07-08 | 2016-08-19 | 인사이트 홀딩스 코포레이션 | 인돌아민 2,3-디옥시게나아제의 억제제로서의 1,2,5-옥사디아졸 |
AU2009270849B2 (en) | 2008-07-17 | 2013-11-21 | Micell Technologies, Inc. | Drug delivery medical device |
EP2350111A1 (en) | 2008-10-15 | 2011-08-03 | Synthon B.V. | Processes and intermediates for the production of fulvestrant |
US20100098659A1 (en) | 2008-10-22 | 2010-04-22 | Revalesio Corporation | Compositions and methods for treating matrix metalloproteinase 9 (mmp9)-mediated conditions |
SI3202420T1 (sl) | 2008-12-11 | 2020-08-31 | Besins Healthcare Luxembourg Sarl | Transdermalni farmacevtski sestavki, ki obsegajo serm |
CN101891635B (zh) * | 2009-05-21 | 2014-06-04 | 扬子江药业集团有限公司 | 枸橼酸他莫昔芬的晶型及晶型a的制备方法 |
US9132084B2 (en) * | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
US20100317635A1 (en) | 2009-06-16 | 2010-12-16 | Endorecherche, Inc. | Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators |
US20120149761A1 (en) | 2009-08-27 | 2012-06-14 | Atossa Genetics, Inc. | Nucleic acid molecules and uses thereof |
US8637569B2 (en) | 2009-10-22 | 2014-01-28 | Api Genesis, Llc | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds |
WO2011072244A1 (en) | 2009-12-10 | 2011-06-16 | Mount Sinai School Of Medicine Of New York University | Method of treatment of breast cancer with tamoxifen |
EP2425833A1 (de) | 2010-09-03 | 2012-03-07 | Fresenius Kabi Deutschland GmbH | Die intravenöse Applikation von Fischöl/DHA +EPA vor bzw. mit Beginn der Chemotherapie |
KR101308258B1 (ko) | 2010-10-15 | 2013-09-13 | 씨제이제일제당 (주) | 엔독시펜의 신규한 제조 방법 |
US9200045B2 (en) | 2011-03-11 | 2015-12-01 | President And Fellows Of Harvard College | Small molecule-dependent inteins and uses thereof |
US20120301541A1 (en) | 2011-05-24 | 2012-11-29 | Haronsky Elina | Compressed core for pharmaceutical composition |
WO2013033430A1 (en) | 2011-09-02 | 2013-03-07 | Wake Forest School Of Medicine | Targeted delivery and prodrug designs for platinum-acridine anti-cancer compounds and methods thereof |
FR2980972B1 (fr) | 2011-10-05 | 2014-02-28 | Commissariat Energie Atomique | Formulations pour le diagnostic et le traitement de cancers hormonodependants et de cancers des organes de synthese d'hormones steroidiennes. |
WO2013134230A1 (en) | 2012-03-05 | 2013-09-12 | Xavier University | Boron-based 4-hydroxytamoxifen and endoxifen prodrugs as treatment for breast cancer |
WO2014012117A1 (en) | 2012-07-13 | 2014-01-16 | South Dakota State University | Compositions and methods for localized drug delivery through mammary papillae |
US20150321983A1 (en) | 2012-10-19 | 2015-11-12 | Fermion Oy | A process for the preparation of ospemifene |
CN104884452A (zh) | 2012-11-20 | 2015-09-02 | 沃泰克斯药物股份有限公司 | 用作吲哚胺2,3-二氧化酶的抑制剂的化合物 |
IL298125A (en) | 2013-02-26 | 2023-01-01 | Memorial Sloan Kettering Cancer Center | Preparations and methods for immunotherapy |
IN2013MU00646A (ko) * | 2013-03-04 | 2015-06-26 | Intas Pharmaceuticals Ltd | |
TW201536278A (zh) * | 2013-05-31 | 2015-10-01 | Del Mar Pharmaceuticals | 雙脫水半乳糖醇及其類似物與衍生物用於治療復發性惡性神經膠瘤或進行性繼發腦瘤之用途 |
CA2927752A1 (en) | 2013-10-18 | 2015-04-23 | The Regents Of The University Of Michigan | Systems and methods for determining a treatment course of action |
HUP1300646A2 (en) | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
EP3092027A4 (en) | 2014-01-10 | 2017-09-06 | Atossa Genetics Inc. | Transpapillary methods and compositions for diagnosing and treating breast conditions |
US9744177B2 (en) | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
US9914696B2 (en) | 2014-03-11 | 2018-03-13 | Repros Therapeutics Inc. | Clomiphene synthesis using a single solvent |
WO2015187727A2 (en) | 2014-06-04 | 2015-12-10 | Atossa Genetics Inc. | Molecular mammography |
CN104230723B (zh) | 2014-08-21 | 2016-08-24 | 凯莱英医药集团(天津)股份有限公司 | 托瑞米芬的合成方法 |
AU2016247674A1 (en) | 2015-04-14 | 2017-10-19 | Atossa Genetics Inc. | Compositions and methods of treatment of breast disorders and estrogen-related disorders |
US20180200206A1 (en) | 2015-07-14 | 2018-07-19 | Atossa Genetics Inc. | Transpapillary methods and compositions for treating breast disorders |
EP3365322B1 (en) * | 2015-10-22 | 2021-05-26 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Process for preparing (z)-endoxifen of high purity |
DE102015222031A1 (de) * | 2015-11-10 | 2017-05-11 | Robert Bosch Gesellschaft Für Medizinische Forschung Mbh | Synthese von (Z)-Endoxifenhydrochlorid |
US20170304232A1 (en) | 2016-04-20 | 2017-10-26 | Northwestern University | Endoxifen For Local Transdermal Therapy To The Breast |
AU2018329202B2 (en) * | 2017-09-11 | 2022-10-27 | Atossa Therapeutics, Inc. | Methods for making and using endoxifen |
US20200268690A1 (en) | 2017-09-11 | 2020-08-27 | Atossa Therapeutics, Inc. | Topical compositions |
WO2019051370A1 (en) | 2017-09-11 | 2019-03-14 | Atossa Genetics Inc. | TOPICAL COMPOSITIONS AND METHODS OF TREATMENT |
-
2018
- 2018-09-10 AU AU2018329202A patent/AU2018329202B2/en active Active
- 2018-09-10 JP JP2020511956A patent/JP2020533283A/ja active Pending
- 2018-09-10 US US16/641,985 patent/US11261151B2/en active Active
- 2018-09-10 SG SG11202002105WA patent/SG11202002105WA/en unknown
- 2018-09-10 KR KR1020207010196A patent/KR20200052349A/ko not_active Application Discontinuation
- 2018-09-10 IL IL272924A patent/IL272924B2/en unknown
- 2018-09-10 MX MX2020002649A patent/MX2020002649A/es unknown
- 2018-09-10 WO PCT/US2018/050272 patent/WO2019051416A1/en unknown
- 2018-09-10 CN CN201880072905.6A patent/CN111328280A/zh active Pending
- 2018-09-10 EP EP18853361.6A patent/EP3681491A4/en active Pending
- 2018-09-10 CA CA3073836A patent/CA3073836A1/en active Pending
- 2018-09-10 TW TW107131790A patent/TWI793165B/zh active
- 2018-09-10 IL IL304863A patent/IL304863A/en unknown
- 2018-09-10 CN CN202310795504.6A patent/CN116832020A/zh active Pending
-
2022
- 2022-01-20 US US17/580,428 patent/US11572334B2/en active Active
- 2022-12-29 US US18/090,757 patent/US11680036B1/en active Active
-
2023
- 2023-01-03 AU AU2023200013A patent/AU2023200013A1/en active Pending
- 2023-03-30 US US18/128,536 patent/US20230365490A1/en active Pending
- 2023-07-18 JP JP2023116961A patent/JP2023126540A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US20230365490A1 (en) | 2023-11-16 |
WO2019051416A1 (en) | 2019-03-14 |
US20230183166A1 (en) | 2023-06-15 |
KR20200052349A (ko) | 2020-05-14 |
EP3681491A1 (en) | 2020-07-22 |
TW201919596A (zh) | 2019-06-01 |
US11261151B2 (en) | 2022-03-01 |
AU2023200013A1 (en) | 2023-02-09 |
US11572334B2 (en) | 2023-02-07 |
IL272924B2 (en) | 2024-01-01 |
US20220242816A1 (en) | 2022-08-04 |
CA3073836A1 (en) | 2019-03-14 |
JP2023126540A (ja) | 2023-09-07 |
IL304863A (en) | 2023-10-01 |
JP2020533283A (ja) | 2020-11-19 |
CN111328280A (zh) | 2020-06-23 |
MX2020002649A (es) | 2020-09-25 |
AU2018329202B2 (en) | 2022-10-27 |
CN116832020A (zh) | 2023-10-03 |
US11680036B1 (en) | 2023-06-20 |
IL272924A (en) | 2020-04-30 |
US20200207704A1 (en) | 2020-07-02 |
AU2018329202A1 (en) | 2020-03-19 |
TWI793165B (zh) | 2023-02-21 |
EP3681491A4 (en) | 2021-06-30 |
IL272924B1 (en) | 2023-09-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL3718370T3 (pl) | Sposoby i powiązane urządzenia służące do realizacji funkcji multi-connectivity | |
SG11202002901TA (en) | Structurally-colored articles and methods for making and using structurally-colored articles | |
GB201701109D0 (en) | Method | |
GB201704847D0 (en) | Callibration method | |
IL272924A (en) | Methods for preparing and using endoxifen | |
GB201706778D0 (en) | Method | |
GB201805021D0 (en) | Method and use | |
GB201805024D0 (en) | Method and use | |
GB201805103D0 (en) | Method and use | |
GB201805042D0 (en) | Method and use | |
GB201709333D0 (en) | Method | |
GB201706544D0 (en) | Method | |
GB201700352D0 (en) | Method | |
GB201703036D0 (en) | Methods | |
GB201702250D0 (en) | Method | |
GB201708853D0 (en) | Method | |
GB201707140D0 (en) | Method | |
DK3615520T3 (en) | Methods | |
GB201705897D0 (en) | Method | |
GB201704536D0 (en) | Method | |
GB201702096D0 (en) | Method | |
GB201701941D0 (en) | Method | |
SG11202000935SA (en) | Cis-polycycloolefins and methods for forming cis-polycycloolefins | |
GB201719043D0 (en) | Methods and compounds | |
GB201705129D0 (en) | Method and use |